Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
dementia
Biotech
Trace uses $101M series A to go after same ALS target as Lilly
Trace Medicine has launched with $101 million and a mission to treat ALS by targeting a protein that recently caught Lilly's attention
James Waldron
Nov 12, 2024 7:00am
Astellas pays $50M for option on AviadoBio dementia gene therapy
Oct 8, 2024 7:40am
Lilly pays QurAlis $45M for preclinical ALS, dementia prospect
Jun 3, 2024 5:00am
Gene inhibition prevents types of brain damage in mice, cells
Apr 8, 2024 7:20am
Eisai backs C2N's Alzheimer's blood tests with up to $15M
Mar 6, 2024 2:54pm
Passage looks to offload lead program, 2 other assets
Dec 20, 2023 1:29pm
